Impact of cardiovascular complications among patients with Type 2 diabetes mellitus: a systematic review
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Macrovascular and microvascular complications that accompany Type 2 diabetes mellitus (T2DM) add to the burden among patients. The purpose of this systematic review is to conduct a comprehensive search of the medical literature investigating the prevalence of cardiovascular (CV) complications and assess their impact on healthcare costs, quality of life and mortality among patients with T2DM in the context of microvascular complications. A total of 76 studies and reports were used in this systematic review. Hypertension was the most prevalent complication among patients with T2DM. The additional cost burden due to CV complications was higher than any other complication except end-stage renal disease. Quality of life was much lower among patients with CV complications and T2DM, and mortality was higher than either illness alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Economic Costs of Diabetes in the U.S. in 2002
American Diabetes Association (2003) · Diabetes Care · doi:10.2337/diacare.26.3.917 · Cited by 4,147
Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus
Scirica, B. M., Bhatt, D. L., Braunwald, E., Steg, P. G., Davidson, J., Hirshberg, B., Ohman, P., Frederich, R., Wiviott, S. D., Hoffman, E. B., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1307684 · Cited by 3,470 · cited 1×
“As a result, newer drugs, such as saxagliptin and alogliptin belonging to the class of dipeptidyl peptidase-4 inhibitors, were recently shown to be CV neutral in separate clinical trials: SAVOR [63] and EXAMINE [64] potentially improving condition and reducing costs in contrast with some antihyperglycemic medications…”
BackgroundAlogliptin after acute coronary syndrome in patients with type 2 diabetes
White, W. B., Cannon, C. P., Heller, S. R., Nissen, S. E., Bergenstal, R. M., Bakris, G. L., Perez, A. T., Fleck, P. R., Mehta, C. R., Kupfer, S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305889 · Cited by 2,502 · cited 1×
“As a result, newer drugs, such as saxagliptin and alogliptin belonging to the class of dipeptidyl peptidase-4 inhibitors, were recently shown to be CV neutral in separate clinical trials: SAVOR [63] and EXAMINE [64] potentially improving condition and reducing costs in contrast with some antihyperglycemic medications…”
BackgroundFenwick, E. K., Xie, J., Ratcliffe, J., Pesudovs, K., Finger, R. P., Wong, T. Y., & Lamoureux, E. L. (2012) · Investigative Opthalmology & Visual Science · doi:10.1167/iovs.11-8992 · Cited by 101 · cited 3×
“In a study done in Australia, the prevalence of hypertension in elderly patients with T2DM was found to be in the same range as that in other studies, with 62% suffering from hypertension [17].”
BackgroundInfluentialStraka, R. J., Liu, L. Z., Girase, P. S., DeLorenzo, A., & Chapman, R. H. (2009) · Cardiovascular Diabetology · doi:10.1186/1475-2840-8-53 · Cited by 67 · cited 2×
“Analysis of national administrative claims according to 2006 costs showed the direct medical costs to be US$26,035 for MI, 11,178 for heart failure, 7038 for angina and 11,802 for stroke in patients with T2DM [27].”
BackgroundGreen, A. J., Bazata, D. D., Fox, K. M., & Grandy, S. (2012) · Cardiology Research and Practice · doi:10.1155/2012/404107 · Cited by 33 · cited 1×
“A study of patients with diabetes in four European countries found that the high prevalence of hypertension and heart failure was related to lower quality of life [42], whereas a study in Singapore found coronary heart disease, nephropathy and peripheral neuropathy were associated with lower scores on a quality of lif…”
Background
Cited by
Evaluating Digital Health Interventions
Murray, E., Hekler, E. B., Andersson, G., Collins, L. M., Doherty, A., Hollis, C., Rivera, D. E., West, R., & Wyatt, J. C. (2016) · American Journal of Preventive Medicine · doi:10.1016/j.amepre.2016.06.008 · Cited by 847
Why primary obesity is a disease?
De Lorenzo, A., Gratteri, S., Gualtieri, P., Cammarano, A., Bertucci, P., & Di Renzo, L. (2019) · Journal of Translational Medicine · doi:10.1186/s12967-019-1919-y · Cited by 370
Economic Burden of Cardiovascular Disease in Type 2 Diabetes: A Systematic Review
Einarson, T. R., Acs, A., Ludwig, C., & Panton, U. H. (2018) · Value in Health · doi:10.1016/j.jval.2017.12.019 · Cited by 305
Diabetes mellitus and stroke: A clinical update
Tun, N. N., Arunagirinathan, G., Munshi, S. K., & Pappachan, J. M. (2017) · World Journal of Diabetes · doi:10.4239/wjd.v8.i6.235 · Cited by 177
Effects of SGLT2 inhibitors and GLP-1 receptor agonists on renin-angiotensin-aldosterone system
Puglisi, S., Rossini, A., Poli, R., Dughera, F., Pia, A., Terzolo, M., & Reimondo, G. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.738848 · Cited by 143
Metadata
- Authors
- Vaidya, V., Gangan, N., & Sheehan, J.
- Venue
- Expert Review of Pharmacoeconomics & Outcomes Research
- Publisher
- Informa UK Limited
- Published
- 2015-03-31
- Volume
- 15
- Issue
- 3
- Pages
- 487-497
- ISSN
- 1473-7167 (ISSN-L)
- 1744-8379
- OpenAlex
- W2158024189
- Cited by
- 120
- References
- 7
- FWCI
- 1.57
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.